ENTITY
Pacific Edge

Pacific Edge (PEB NZ)

58
Analysis
Health Care • New Zealand
Pacific Edge Ltd is a biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. The Company has completed successful trials in bladder cancer detection and colorectal cancer prognosis.
more
bearish•Pacific Edge
•02 Dec 2025 13:00•Broker

Pacific Edge 1H26 Result—Still Waiting for a CMS Pulse

PEB was reluctant to give guidance but committed to a lower cash burn in 2H26 versus 1H26 (we forecast ~NZ$2.6m a month versus ~NZ$3.2m in 1H26).

Logo
149 Views
Share
bearish•Pacific Edge
•09 Jun 2025 12:00•Broker

Pacific Edge FY25 Result—Dipping Back Into the Well

Pacific Edge's FY25 revenue was consistent with expectations, while costs were slightly higher than anticipated. Non-CMS US revenue grew by...

Logo
283 Views
Share
bearish•Pacific Edge
•04 May 2025 12:00•Broker

Pacific Edge Another Blow

Pacific Edge (PEB) will no longer receive CMS reimbursement for its Cxbladder tests, which constituted 60%-70% of its revenue.

Logo
339 Views
Share
bullish•Pacific Edge
•08 Mar 2025 13:00•Broker

Pacific Edge - Draws First Blood in the Latest Novitas Battle

Pacific Edge’s (PEB) Cxbladder Triage test has been included in the American Urological Association’s (AUA) amended microhematuria guidelines.

Logo
717 Views
Share
bearish•Pacific Edge
•14 Jan 2025 21:58•Broker

Pacific Edge - A Big Blow

Pacific Edge (PEB) is set to no longer receive reimbursement for its Cxbladder tests from CMS in the US from 23 February 2025.

Logo
447 Views
Share
x